A5076616410- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Melanoma and MAPK Pathways
- Colorectal Cancer Treatments and Studies
- Occupational and environmental lung diseases
- Peptidase Inhibition and Analysis
- Cancer Mechanisms and Therapy
- Cancer Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Cutaneous Melanoma Detection and Management
- Neuroendocrine Tumor Research Advances
- Radiomics and Machine Learning in Medical Imaging
- PI3K/AKT/mTOR signaling in cancer
- Multiple and Secondary Primary Cancers
- Cancer Genomics and Diagnostics
- Medical Imaging Techniques and Applications
- Cancer therapeutics and mechanisms
- Colorectal and Anal Carcinomas
- Economic and Financial Impacts of Cancer
- Gastric Cancer Management and Outcomes
- Chromatin Remodeling and Cancer
- CAR-T cell therapy research
Azienda USL di Bologna
2020-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2021-2024
University of Bologna
2018-2023
Policlinico S.Orsola-Malpighi
2008-2021
Medica (Italy)
2020
Targeted therapies for melanoma have shown clinical benefit in increasing the survival of metastatic patients. Cutaneous adverse events been reported, but hair and nail data rarely detailed. Patients treated with BRAF MEK inhibitors underwent dermatological evaluation before start each treatment after every four weeks. Pull test, global photography, dermoscopy/trichoscopy scalp biopsy were performed. Appendages graded using National Cancer Institute's Common Terminology Criteria. Of 24...
Background/Aim: Brain metastases are an additional challenge in patients with non-small-cell lung cancer (NSCLC) because most chemotherapy agents cannot cross the blood–brain barrier. Nivolumab has demonstrated efficacy advanced squamous NSCLC, but central nervous system (CNS) typically excluded from registration trials, 'field-practice' data needed. Patients and Methods: Italian cohort of Expanded Access Program (EAP) who had CNS at baseline were analyzed. Results: Thirty-seven received a...
Abstract Background Despite sensitivity to first-line chemotherapy, most small-cell lung cancer (SCLC) patients relapse. In this setting, topotecan demonstrated modest activity with significant toxicity. Paclitaxel was also active. This study designed evaluate and safety of nab-paclitaxel in relapsed SCLC. Methods multicentre prospective Phase 2 trial, refractory or sensitive SCLC progressed platinum-based chemotherapy received 100 mg/smq on days 1, 8, 15 every 4 weeks up six cycles,...
BRAF mutation involved 2-4% of lung adenocarcinoma. Differences in clinicopathologic features and patient outcome exist between V600E non-V600E mutated NSCLC. Thus, we sought to assess the frequency clinical relevance mutations a real-life population advanced-NSCLC, investigating potential prognostic significance distinct genetic alterations.The present multicenter Italian retrospective study advanced mutant Complete data were evaluated for patients.A total 44 BRAFmut NSCLC patients included...
Hyponatremia in cancer patients is often caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH). The aim this observational multicenter study was to analyze medical and economic implications SIADH setting. This included 90 oncological from 28 Italian institutions that developed between January 2010 September 2015. Data on clinical-pathological characteristics, anticancer therapies, hyponatremia, related treatments were statistically analyzed. majority lung (73%) with...
The impact of baseline versus intercurrent steroids on the efficacy upfront chemotherapy plus pembrolizumab (CT-ICI) for advanced non-small cell lung cancer (NSCLC) patients is unclear. We conducted a retrospective study metastatic NSCLC treated with CT-ICI at our institution between March 2020 and December 2021. use was considered as administration least 10 mg prednisone equivalent. Of 101 patients, 36 (35.6%) received steroid therapy baseline, 18 (17.8%) started treatment. Overall, median...
In non-small cell lung cancer (NSCLC), BRAF class 1 alterations are effectively targeted by inhibitors. Conversely, therapies have very low or absent activity in patients carrying 2 and 3 alterations. The spectrum of NSCLC patients, their accompanying clinical features, genomic landscape treatment outcomes been poorly reported.We identified defined functional across different tumors through a systematic review. Then, we selected alterations, according to the review, cBioPortal (cBioPortal...
Background: An acceptable risk-benefit ratio may encourage the prescription of immune checkpoint inhibitors (ICI) near late stage life. The lung prognostic index (LIPI) was validated in advanced non-small cell cancer (NSCLC) patients treated with ICIs. palliative (PaP) score without clinical prediction survival (PaPwCPS) predicts early mortality probability terminal patients. Methods: We performed a retrospective study including 182 deceased NSCLC patients, single-agent ICI at our...